Table 2.
Predictive Ability of the RAI-C, RAI-A, and mFIa
| Outcome | 6856 Patients With Mortality |
2785 Patients With RAI-A |
1021 Patients With mFI |
|---|---|---|---|
| C statistic (95% CI) | C statistic (95% CI) | C statistic (95% CI) | |
| RAI-Cb | |||
| Mortality | |||
| 30-d | 0.704 (0.594–0.814) | 0.744 (0.588–0.899) | 0.823 (0.590–1.000) |
| 180-d | 0.772 (0.726–0.817) | 0.824 (0.767–0.881) | 0.797 (0.707–0.887) |
| 365-d | 0.781 (0.748–0.814) | 0.814 (0.770–0.859) | 0.811 (0.741–0.882) |
| Any except SSI and UTI | NA | 0.646 (0.599–0.693) | 0.643 (0.573–0.713) |
| Clavien-Dindo IV | NA | 0.656 (0.595–0.717) | 0.615 (0.533–0.696) |
| RAI-A | |||
| Mortality | |||
| 30-d | NA | 0.901 (0.861–0.940) | 0.979 (0.952–1.000) |
| 180-d | NA | 0.823 (0.763–0.883) | 0.865 (0.769–0.961) |
| 365-d | NA | 0.797 (0.750–0.843) | 0.846 (0.772–0.920) |
| Any except SSI and UTI | NA | 0.618 (0.570–0.667) | 0.614 (0.539–0.689) |
| Clavien-Dindo IV | NA | 0.577 (0.510–0.644) | 0.586 (0.499–0.674) |
| mFIc | |||
| Mortality | |||
| 30-d | NA | NA | 0.957 (0.915–0.999) |
| 180-d | NA | NA | 0.811 (0.708–0.914) |
| 365-d | NA | NA | 0.739 (0.652–0.825) |
| Any except SSI and UTI | NA | NA | 0.662 (0.594–0.731) |
| Clavien-Dindo IV | NA | NA | 0.642 (0.559–0.725) |
Abbreviations: mFI, Modified Frailty Index; NA, not available; RAI, Risk Analysis Index; RAI-A, Administrative Risk Analysis Index; RAI-C, Clinical Risk Analysis Index; SSI, superficial site infection; UTI, urinary tract infection.
Table reports the area under the receiver operating characteristic (C statistic) for multiple models predicting either mortality or complications. Separate models for 30-day, 180-day and 365-day mortality were computed for each cohort. The 2 composite complication outcomes included either (1) severe, Clavien-Dindo level IV complications or (2) any complication except SSI or UTI. Outcome data were complete for the 2785 and 1021 patients with RAI-A and mFI scores, respectively. Of the 6856 patients with RAI-C scores, 6803, 6419, and 5959 were followed up for 30, 180 and 365 days, respectively.